Looking Back on Dermatology's Historic 2023 with Raj Chovatiya, MD, PhD

2023 was a year of both advancements and setbacks for various treatments, and this discussion covers the most significant moves by the FDA this year.

Related Keywords

Eli Lilly ,Smitht Lawrence Eichenfield ,Raj Chovatiya ,Verrica Pharmaceuticals ,Northwestern University Feinberg School Of Medicine ,Drug Administration ,Northwestern University ,Feinberg School ,Complete Response Letter ,Biologics License Application ,Gene Therapy ,Dystrophic Epidermolysis ,First Drug ,Adolescent Alopecia ,First Triple Combination Drug ,Secukinumab Mean ,Approve Dupilumab ,Lebrikizumab Treatment ,Atopic Dermatitis ,Eczema ,Dhs ,Molluscum ,Deb ,